Diagnosis and Management of Ischemic Heart Disease

 

 Buy Article Permissions and Reprints

Abstract

Ischemic heart disease (IHD) is the leading cause of death and disability worldwide. An early and accurate diagnosis of IHD is necessary to improve outcomes. According to recent guidelines, the diagnosis of acute myocardial infarction (AMI) is based on increased or decreased value of cardiospecific troponins with one measure exceeding the 99th percentile upper reference limit, associated with symptoms suggestive for myocardial ischemia, indicative electrocardiogram abnormalities, and evidence of recent myocardial functional impairment or intracoronary thrombosis. The recent advent of highly sensitive troponin immunoassays has represented a paradigm shift, wherein the improved analytical sensitivity has increased the negative predictive value, while contextually decreasing the diagnostic specificity of these tests. Although several additional biomarkers have been proposed as surrogate or in combination with troponins, there is little evidence that any of these will substantially improve AMI diagnosis. With regard to therapy, early mechanical (i.e., percutaneous coronary intervention, PCI) or pharmacological reperfusion should be performed early in ST-segment elevation myocardial infarction (STEMI) within 12 h of symptom onset, whereas fibrinolysis may be considered in all other circumstances. Patients undergoing primary PCI should also receive a combination of double antiplatelet therapy (i.e., aspirin and adenosine diphosphate receptor blocker), associated with parenteral anticoagulation, preferably with low-molecular-weight heparin. In analogy with STEMI, a wealth of data shows that primary early invasive strategy (i.e., PCI) and antiplatelet therapy remains the cornerstone of management of patients with non-ST segment elevation acute coronary syndrome. Stem cell–based therapy has also emerged as a potentially therapeutic option, and there are ongoing efforts among several investigators to translate basic research into clinical practice.

• References

• 1 Roger VL, Go AS, Lloyd-Jones DM , et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation 2012; 125 (1) 188-197
  CrossrefPubMedGoogle Scholar
• 2 Thygesen K, Alpert JS, Jaffe AS , et al. Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction; Authors/Task Force Members Chairpersons; Biomarker Subcommittee; ECG Subcommittee; Imaging Subcommittee; Classification Subcommittee; Intervention Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; ESC Committee for Practice Guidelines (CPG); Document Reviewers. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012; 60 (16) 1581-1598
  CrossrefPubMedGoogle Scholar
• 3 Lanza GA, Careri G, Crea F. Mechanisms of coronary artery spasm. Circulation 2011; 124 (16) 1774-1782
  CrossrefPubMedGoogle Scholar
• 4 Tofler GH, Muller JE. Triggering of acute cardiovascular disease and potential preventive strategies. Circulation 2006; 114 (17) 1863-1872
  CrossrefPubMedGoogle Scholar
• 5 Lippi G, Favaloro EJ, Cervellin G. Massive posttraumatic bleeding: epidemiology, causes, clinical features, and therapeutic management. Semin Thromb Hemost 2012; (e-pub ahead of print). DOI: 10.1055/s-0032-1328936.
  PubMedGoogle Scholar
• 6 Lippi G, Plebani M, Cervellin G. Cocaine in acute myocardial infarction. Adv Clin Chem 2010; 51: 53-70
  PubMedGoogle Scholar
• 7 Steg PG, James SK, Atar D , et al. Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); Document Reviewers. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33 (20) 2569-2619
  CrossrefPubMedGoogle Scholar
• 8 Hamm CW, Bassand JP, Agewall S , et al. ESC Committee for Practice Guidelines; Document Reviewers. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32 (23) 2999-3054
  CrossrefPubMedGoogle Scholar
• 9 Roger VL, Go AS, Lloyd-Jones DM , et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation 2012; 125 (1) 188-197
  CrossrefPubMedGoogle Scholar
• 10 Giugliano RP, Braunwald E. The Year in Non-ST-Segment Elevation Acute Coronary Syndrome. J Am Coll Cardiol 2012; 60 (21) 2127-2139
  CrossrefPubMedGoogle Scholar
• 11 Kawai S, Suzuki H, Yamaguchi H , et al. Ampulla cardiomyopathy (‘Takotusbo’ cardiomyopathy)—reversible left ventricular dysfunction: with ST segment elevation. Jpn Circ J 2000; 64 (2) 156-159
  CrossrefPubMedGoogle Scholar
• 12 Pilgrim TM, Wyss TR. Takotsubo cardiomyopathy or transient left ventricular apical ballooning syndrome: A systematic review. Int J Cardiol 2008; 124 (3) 283-292
  CrossrefPubMedGoogle Scholar
• 13 Abraham J, Mudd JO, Kapur NK, Klein K, Champion HC, Wittstein IS. Stress cardiomyopathy after intravenous administration of catecholamines and beta-receptor agonists. J Am Coll Cardiol 2009; 53 (15) 1320-1325
  CrossrefPubMedGoogle Scholar
• 14 Eshtehardi P, Koestner SC, Adorjan P , et al. Transient apical ballooning syndrome—clinical characteristics, ballooning pattern, and long-term follow-up in a Swiss population. Int J Cardiol 2009; 135 (3) 370-375
  CrossrefPubMedGoogle Scholar
• 15 Kolh P, Wijns W, Danchin N , et al. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI). Guidelines on myocardial revascularization. Eur J Cardiothorac Surg 2010; 38 (Suppl): S1-S52
  CrossrefPubMedGoogle Scholar
• 16 Lippi G, Targher G, Franchini M, Plebani M. Genetic and biochemical heterogeneity of cardiac troponins: clinical and laboratory implications. Clin Chem Lab Med 2009; 47 (10) 1183-1194
  CrossrefPubMedGoogle Scholar
• 17 Apple FS. Counterpoint: Standardization of cardiac troponin I assays will not occur in my lifetime. Clin Chem 2012; 58 (1) 169-171
  CrossrefPubMedGoogle Scholar
• 18 Lippi G, Cervellin G, Aloe R, Montagnana M, Salvagno GL, Guidi GC. Non-commutability of results of highly sensitive troponin I and T immunoassays. Biochem Med (Zagreb) 2012; 22 (1) 127-129
  PubMedGoogle Scholar
• 19 Guidi GC, Lippi G. Molar expression: Interconverting results of highly sensitive troponin I and T while preserving clinical significance. Clin Biochem 2012; 45 (1–2) 183
  CrossrefPubMedGoogle Scholar
• 20 Lippi G, Cervellin G. [Standardised designation of commercial troponin immunoassays]. Kardiol Pol 2012; 70 (10) 1095-1096
  PubMedGoogle Scholar
• 21 Apple FS, Collinson PO. IFCC Task Force on Clinical Applications of Cardiac Biomarkers. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012; 58 (1) 54-61
  CrossrefPubMedGoogle Scholar
• 22 Lippi G, Cervellin G, Plebani M. Sensitive cardiac troponin T assay. N Engl J Med 2010; 362 (13) 1242 , author reply 1243
  CrossrefPubMedGoogle Scholar
• 23 Lippi G, Cervellin G, Banfi G, Plebani M. Cardiac troponins and physical exercise. It's time to make a point. Biochem Med (Zagreb) 2011; 21 (1) 55-62
  PubMedGoogle Scholar
• 24 Lippi G, Cervellin G. Identification of troponin determinants for improving its diagnostic performance in the emergency department. J Emerg Med 2012; 43 (6) e487-e488
  CrossrefPubMedGoogle Scholar
• 25 Lippi G, Rastelli G, Meschi T, Borghi L, Cervellin G. Pathophysiology, clinics, diagnosis and treatment of heart involvement in carbon monoxide poisoning. Clin Biochem 2012; 45 (16–17) 1278-1285
  CrossrefPubMedGoogle Scholar
• 26 Newby LK, Jesse RL, Babb JD , et al. ACCF 2012 Expert Consensus Document on Practical Clinical Considerations in the Interpretation of Troponin Elevations: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2012; 60 (23) 2427-2463
  CrossrefPubMedGoogle Scholar
• 27 Thygesen K, Mair J, Giannitsis E , et al. Study Group on Biomarkers in Cardiology of ESC Working Group on Acute Cardiac Care. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012; 33 (18) 2252-2257
  CrossrefPubMedGoogle Scholar
• 28 Lippi G, Montagnana M, Aloe R, Cervellin G. Highly sensitive troponin immunoassays: navigating between the scylla and charybdis. Adv Clin Chem 2012; 58: 1-29
  PubMedGoogle Scholar
• 29 Lippi G, Cervellin G. Degradation of troponin I in serum or plasma: mechanisms, and analytical and clinical implications. Semin Thromb Hemost 2012; 38 (2) 222-229
  Article in Thieme ConnectPubMedGoogle Scholar
• 30 Haaf P, Drexler B, Reichlin T , et al. High-sensitivity cardiac troponin in the distinction of acute myocardial infarction from acute cardiac noncoronary artery disease. Circulation 2012; 126 (1) 31-40
  CrossrefPubMedGoogle Scholar
• 31 Lippi G, Cervellin G. Letter by Lippi and Cervellin regarding article, “High-sensitivity cardiac troponin in the distinction of acute myocardial infarction from acute cardiac noncoronary artery disease.”. Circulation In press. DOI: 10.1161/CIRCULATIONAHA.112.128603.
  PubMedGoogle Scholar
• 32 Reichlin T, Irfan A, Twerenbold R , et al. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. Circulation 2011; 124 (2) 136-145
  CrossrefPubMedGoogle Scholar
• 33 Lippi G, Cervellin G, Robuschi E , et al. Comparison of high sensitivity and contemporary troponin I immunoassays for the early detection of acute myocardial infarction in the emergency department. Ann Clin Biochem 2012; 49 (Pt 2) 205-206
  CrossrefPubMedGoogle Scholar
• 34 Lippi G, Montagnana M, Salvagno GL, Guidi GC. Potential value for new diagnostic markers in the early recognition of acute coronary syndromes. CJEM 2006; 8 (1) 27-31
  PubMedGoogle Scholar
• 35 Lippi G. Biomarkers of myocardial ischemia in the emergency room: cardiospecific troponin and beyond. Eur J Intern Med 2012; ; DOI: 10.1016/j.ejim.2012.10.012.
  PubMedGoogle Scholar
• 36 Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007; 27 (1) 15-26
  CrossrefPubMedGoogle Scholar
• 37 Lindahl B. Are there really biomarkers of vulnerable plaque?. Clin Chem 2012; 58 (1) 151-153
  CrossrefPubMedGoogle Scholar
• 38 Lippi G, Mattiuzzi C, Cervellin G. Pregnancy-associated plasma protein A (PAPP-A) for the early diagnosis of myocardial infarction: more doubts than certainties. Indian Heart J 2012; 64 (6) 625-626
  PubMedGoogle Scholar
• 39 Lippi G, Montagnana M, Salvagno GL , et al. Risk stratification of patients with acute myocardial infarction by quantification of circulating monocyte-platelet aggregates. Int J Cardiol 2007; 115 (1) 101-102
  CrossrefPubMedGoogle Scholar
• 40 Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol 2011; 8 (9) 502-512
  CrossrefPubMedGoogle Scholar
• 41 Lippi G, Cervellin G, Franchini M, Favaloro EJ. Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future. J Thromb Thrombolysis 2010; 30 (4) 459-471
  CrossrefPubMedGoogle Scholar
• 42 Hogg K, Wells PS, Gandara E. The diagnosis of venous thromboembolism. Semin Thromb Hemost 2012; 38 (7) 691-701
  Article in Thieme ConnectPubMedGoogle Scholar
• 43 Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. Semin Thromb Hemost 2012; 38 (7) 673-682
  Article in Thieme ConnectPubMedGoogle Scholar
• 44 Lippi G, Filippozzi L, Montagnana M, Salvagno GL, Guidi GC. Diagnostic value of D-dimer measurement in patients referred to the emergency department with suspected myocardial ischemia. J Thromb Thrombolysis 2008; 25 (3) 247-250
  CrossrefPubMedGoogle Scholar
• 45 Lippi G, Montagnana M, Guidi GC. Albumin cobalt binding and ischemia modified albumin generation: an endogenous response to ischemia?. Int J Cardiol 2006; 108 (3) 410-411
  CrossrefPubMedGoogle Scholar
• 46 Lippi G, Montagnana M. Ischemia-modified albumin in ischemic disorders. Ann Thorac Cardiovasc Surg 2009; 15 (2) 137
  PubMedGoogle Scholar
• 47 Lippi G, Mattiuzzi C, Comelli I, Cervellin G. Glycogen phosphorylase isoenzyme BB in the diagnosis of acute myocardial infarction: a meta-analysis. Biochem Med (Zagreb) . In press
  PubMedGoogle Scholar
• 48 Brancaccio P, Lippi G, Maffulli N. Biochemical markers of muscular damage. Clin Chem Lab Med 2010; 48 (6) 757-767
  CrossrefPubMedGoogle Scholar
• 49 Cervellin G, Comelli I, Lippi G. Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med 2010; 48 (6) 749-756
  CrossrefPubMedGoogle Scholar
• 50 Di Somma S, Navarin S, Giordano S , et al. The emerging role of biomarkers and bio-impedance in evaluating hydration status in patients with acute heart failure. Clin Chem Lab Med 2012; 0 (0) 1-13 DOI: 10.1515/cclm-2012-0289.
  PubMedGoogle Scholar
• 51 Zeng X, Li L, Su Q. The prognostic value of N-terminal pro-brain natriuretic peptide in non-ST elevation acute coronary syndromes: a meta-analysis. Clin Chem Lab Med 2012; 50 (4) 731-739
  PubMedGoogle Scholar
• 52 Montagnana M, Lippi G, Danese E, Salvagno GL, Cervellin G, Guidi GC. Serum concentration of neopterin on admission does not improve the diagnostic performance of highly-sensitive troponin I. Clin Chem Lab Med 2012; 50 (4) 747-748
  PubMedGoogle Scholar
• 53 Lippi G, Plebani M, Di Somma S , et al. Considerations for early acute myocardial infarction rule-out for emergency department chest pain patients: the case of copeptin. Clin Chem Lab Med 2012; 50 (2) 243-253
  PubMedGoogle Scholar
• 54 Sun Y, Zhang K, Fan G, Li J. Identification of circulating microRNAs as biomarkers in cancers: what have we got?. Clin Chem Lab Med 2012; 1-6 . DOI: 10.1515/cclm-2012-0360.
  PubMedGoogle Scholar
• 55 Lippi G, Mattiuzzi C, Cervellin G. Circulating microRNAs (miRs) for diagnosing acute myocardial infarction: Meta-analysis of available studies. Int J Cardiol 2012; ;pii, S0167-5273(12):01273–01279 DOI: 10.1016/j.ijcard.2012.09.152
  PubMedGoogle Scholar
• 56 Lippi G, Cervellin G, Targher G. Random plasma glucose measurement may improve the diagnostic specificity of highly sensitive troponin in the emergency department. Int J Cardiol 2012; 155 (1) 172-173
  CrossrefPubMedGoogle Scholar
• 57 Lippi G, Mattiuzzi C, Comelli I, Cervellin G. Mean platelet volume in patients with ischemic heart disease: meta-analysis of diagnostic studies. Blood Coagul Fibrinolysis 2013; 24 (2) 216-219
  PubMedGoogle Scholar
• 58 Montagnana M, Cervellin G, Meschi T, Lippi G. The role of red blood cell distribution width in cardiovascular and thrombotic disorders. Clin Chem Lab Med 2012; 50 (4) 635-641
  PubMedGoogle Scholar
• 59 Luepker RV, Raczynski JM, Osganian S , et al. Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease: The Rapid Early Action for Coronary Treatment (REACT) trial. JAMA 2000; 284 (1) 60-67
  CrossrefPubMedGoogle Scholar
• 60 Henry TD, Sharkey SW, Burke MN , et al. A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction. Circulation 2007; 116 (7) 721-728
  CrossrefPubMedGoogle Scholar
• 61 Comelli I, Vignali L, Rolli A, Lippi G, Cervellin G. Achievement of a median door-to-balloon time of less than 90 minutes by implementation of organizational changes in the 'Emergency Department to Cath Lab' pathway: a 5-year analysis. J Eval Clin Pract 2012; 18 (4) 788-792
  CrossrefPubMedGoogle Scholar
• 62 Scharf RE. Drugs that affect platelet function. Semin Thromb Hemost 2012; 38 (8) 865-883
  Article in Thieme ConnectPubMedGoogle Scholar
• 63 Yusuf S, Mehta SR, Chrolavicius S , et al. OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006; 295 (13) 1519-1530
  CrossrefPubMedGoogle Scholar
• 64 Mehran R, Lansky AJ, Witzenbichler B , et al. HORIZONS-AMI Trial Investigators. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009; 374 (9696) 1149-1159
  CrossrefPubMedGoogle Scholar
• 65 Stone GW, Witzenbichler B, Guagliumi G , et al; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358 (21) 2218-2230
  CrossrefPubMedGoogle Scholar
• 66 [No authors listed]. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343 (8893) 311-322
  PubMedGoogle Scholar
• 67 Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348 (9030) 771-775
  CrossrefPubMedGoogle Scholar
• 68 Danchin N, Coste P, Ferrières J , et al. FAST-MI Investigators. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the french registry on acute ST-elevation myocardial infarction (FAST-MI). Circulation 2008; 118 (3) 268-276
  CrossrefPubMedGoogle Scholar
• 69 Bonnefoy E, Steg PG, Boutitie F , et al. CAPTIM Investigators. Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up. Eur Heart J 2009; 30 (13) 1598-1606
  CrossrefPubMedGoogle Scholar
• 70 Jneid H, Anderson JL, Wright RS , et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012; 60 (7) 645-681
  CrossrefPubMedGoogle Scholar
• 71 Lippi G, Favaloro EJ, Salvagno GL, Franchini M. Laboratory assessment and perioperative management of patients on antiplatelet therapy: from the bench to the bedside. Clin Chim Acta 2009; 405 (1-2) 8-16
  CrossrefPubMedGoogle Scholar
• 72 Linden MD, Tran H, Woods R, Tonkin A. High platelet reactivity and antiplatelet therapy resistance. Semin Thromb Hemost 2012; 38 (2) 200-212
  Article in Thieme ConnectPubMedGoogle Scholar
• 73 Cattaneo M. Diagnosis and management of high platelet reactivity on treatment with clopidogrel. Semin Thromb Hemost 2012; 38 (7) 645-651
  Article in Thieme ConnectPubMedGoogle Scholar
• 74 Mehta SR, Yusuf S. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 2000; 21 (24) 2033-2041
  CrossrefPubMedGoogle Scholar
• 75 Hulot JS, Collet JP, Cayla G , et al. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv 2011; 4 (5) 422-428
  CrossrefPubMedGoogle Scholar
• 76 Krishna V, Diamond GA, Kaul S. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: the role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven. Circulation 2012; 125 (10) 1288-1303 , discussion 1303
  CrossrefPubMedGoogle Scholar
• 77 Wiviott SD, Braunwald E, McCabe CH , et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357 (20) 2001-2015
  CrossrefPubMedGoogle Scholar
• 78 Wallentin L, Becker RC, Budaj A , et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11) 1045-1057
  CrossrefPubMedGoogle Scholar
• 79 Tello-Montoliu A, Tomasello SD, Ferreiro JL , et al. Pharmacodynamic effects of prasugrel dosing regimens in patients on maintenance prasugrel therapy: results of a prospective randomized study. J Am Coll Cardiol 2012; 59 (19) 1681-1687
  CrossrefPubMedGoogle Scholar
• 80 Mahaffey KW, Wojdyla DM, Carroll K , et al; PLATO Investigators. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011; 124 (5) 544-554
  CrossrefPubMedGoogle Scholar
• 81 James SK, Storey RF, Khurmi NS , et al. PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation 2012; 125 (23) 2914-2921
  CrossrefPubMedGoogle Scholar
• 82 Goodman SG, Clare R, Pieper KS , et al. Platelet Inhibition and Patient Outcomes Trial Investigators. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation 2012; 125 (8) 978-986
  CrossrefPubMedGoogle Scholar
• 83 Gwon HC, Hahn JY, Park KW , et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012; 125 (3) 505-513
  CrossrefPubMedGoogle Scholar
• 84 Park SJ, Park DW, Kim YH , et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362 (15) 1374-1382
  CrossrefPubMedGoogle Scholar
• 85 Valgimigli M, Campo G, Monti M , et al. Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012; 125 (16) 2015-2026
  CrossrefPubMedGoogle Scholar
• 86 Tricoci P, Huang Z, Held C , et al. TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366 (1) 20-33
  CrossrefPubMedGoogle Scholar
• 87 Morrow DA, Braunwald E, Bonaca MP , et al. TRA 2P–TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366 (15) 1404-1413
  CrossrefPubMedGoogle Scholar
• 88 Favaloro EJ, Lippi G. The new oral anticoagulants and the future of haemostasis laboratory testing. Biochem Med (Zagreb) 2012; 22 (3) 329-341
  PubMedGoogle Scholar
• 89 Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology 2011; 43 (7) 682-692
  CrossrefPubMedGoogle Scholar
• 90 Mega JL, Braunwald E, Wiviott SD , et al. ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366 (1) 9-19
  CrossrefPubMedGoogle Scholar
• 91 Tricoci P, Newby LK, Hasselblad V , et al. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials. Circ Cardiovasc Qual Outcomes 2011; 4 (4) 448-458
  CrossrefPubMedGoogle Scholar
• 92 Levine GN, Bates ER, Blankenship JC , et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58 (24) e44-e122
  CrossrefPubMedGoogle Scholar
• 93 Siu CW, Liao S-Y, Liu Y, Lian Q, Tse H-F. Stem cells for myocardial repair. Thromb Haemost 2010; 104 (1) 6-12
  Article in Thieme ConnectPubMedGoogle Scholar
• 94 Arnous S, Mozid A, Martin J, Mathur A. Bone marrow mononuclear cells and acute myocardial infarction. Stem Cell Res Ther 2012; 3 (1) 2
  CrossrefPubMedGoogle Scholar
• 95 Menasché P. Stem cells for clinical use in cardiovascular medicine: current limitations and future perspectives. Thromb Haemost 2005; 94 (4) 697-701
  PubMedGoogle Scholar
• 96 Quaini F, Urbanek K, Beltrami AP , et al. Chimerism of the transplanted heart. N Engl J Med 2002; 346 (1) 5-15
  CrossrefPubMedGoogle Scholar
• 97 Fedak PW. Paracrine effects of cell transplantation: modifying ventricular remodeling in the failing heart. Semin Thorac Cardiovasc Surg 2008; 20 (2) 87-93
  CrossrefPubMedGoogle Scholar
• 98 Strauer BE, Brehm M, Zeus T , et al. [Intracoronary, human autologous stem cell transplantation for myocardial regeneration following myocardial infarction]. Dtsch Med Wochenschr 2001; 126 (34-35) 932-938
  Article in Thieme ConnectPubMedGoogle Scholar
• 99 Donndorf P, Strauer BE, Steinhoff G. Update on cardiac stem cell therapy in heart failure. Curr Opin Cardiol 2012; 27 (2) 154-160
  CrossrefPubMedGoogle Scholar
• 100 George JC. Stem cell therapy in acute myocardial infarction: a review of clinical trials. Transl Res 2010; 155 (1) 10-19
  CrossrefPubMedGoogle Scholar
• 101 Mozid AM, Arnous S, Sammut EC, Mathur A. Stem cell therapy for heart diseases. Br Med Bull 2011; 98: 143-159
  CrossrefPubMedGoogle Scholar
• 102 Sanz-Ruiz R, Gutiérrez Ibañes E, Arranz AV, Fernández Santos ME, Fernández PL, Fernández-Avilés F. Phases I–III clinical trials using adult stem cells. Stem Cells Int 2010; 2010: 579142
  PubMedGoogle Scholar
• 103 Wen Y, Meng L, Xie J, Ouyang J. Direct autologous bone marrow-derived stem cell transplantation for ischemic heart disease: a meta-analysis. Expert Opin Biol Ther 2011; 11 (5) 559-567
  CrossrefPubMedGoogle Scholar
• 104 Donndorf P, Kundt G, Kaminski A , et al. Intramyocardial bone marrow stem cell transplantation during coronary artery bypass surgery: a meta-analysis. J Thorac Cardiovasc Surg 2011; 142 (4) 911-920
  CrossrefPubMedGoogle Scholar
• 105 ClinicalTrials.gov. Available from: http://www.ClinicalTrials.gov . Accessed November 20, 2012
  PubMedGoogle Scholar
• 106 Lippi G, Favaloro EJ. Antisense therapy in the treatment of hypercholesterolemia. Eur J Intern Med 2011; 22 (6) 541-546
  CrossrefPubMedGoogle Scholar
• 107 Lippi G, Mattiuzzi C, Favaloro EJ. Novel and emerging therapies: thrombus-targeted fibrinolysis. Semin Thromb Hemost 2012; (e-pub ahead of print). DOI: DOI: 10.1055/s-0032-1328935.
  PubMedGoogle Scholar